ROIV
LONGINSIDER SELLROIVANT SCIENCES LTD
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.
News Summary
PositiveRoivant delivered a major earnings beat in Q4 FY2026 (+196% EPS surprise) and secured a transformative $2.25B Moderna settlement ($771.6M received July 2026), validating its LNP IP and providing substantial capital for operations and buybacks. However, revenue declined 33.6% YoY to $1.44M in Q1 FY2027, R&D spending remains elevated at $202M quarterly, and the company is discontinuing batoclimab while betting heavily on pipeline assets like brepocitinib (PDUFA Q3 2026) and IMVT-1402.
Red flags
- •Revenue declining significantly (down 33.6% YoY in Q1 FY2027 to $1.44M)
- •Batoclimab Phase 3 failures in thyroid eye disease; first-generation program discontinued
- •Heavy R&D burn ($202M per quarter) creates dependency on pipeline clinical success
- •Moderna settlement includes contingent payment contingent on appellate outcome (up to $1.3B at risk)
Funds Buying (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | 6.7M | +209K | $184M | 0.5% | +3% | Existing |
| Greenlight Capital | David Einhorn | 2.2M | +83K | $60M | 1.9% | +4% | Existing |
| Maverick Capital | Lee Ainslie | 1.6M | +1.6M | $45M | 0.5% | — | NEW |
| Point72 | Steve Cohen | 891K | +891K | $25M | <0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where ROIV ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #18 of this fund's book
- 15TD SYNNEX CORPORATION$81M
- 16BKV CORP$77M
- 17LIBERTY GLOBAL LTD$60M
- 18ROIVANT SCIENCES LTD$60M
- 19CROCS INC$56M
- 20RESIDEO TECHNOLOGIES INC$53M
- 21DECKERS OUTDOOR CORP$48M
Values are quarter-end position sizes. Shown only for funds where ROIV ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO | SELL | 200K | $34.95 | $6.99M | 2026-07-27 | ↗ |
| Fitzgerald Meghan | — | SELL | 10K | $34.90 | $0.35M | 2026-06-30 | ↗ |
| Gold Daniel Allen | — | SELL | 12K | $35.28 | $0.44M | 2026-06-30 | ↗ |
| MANCHESTER KEITH S | — | SELL | 12K | $35.28 | $0.44M | 2026-06-30 | ↗ |
| MANCHESTER KEITH S | — | SELL | 200K | $35.45 | $7.09M | 2026-06-30 | ↗ |
| QVT Financial LP | — | SELL | 12K | $35.28 | $0.44M | 2026-06-30 | ↗ |
| MANCHESTER KEITH S | — | SELL | 200K | $34.44 | $6.89M | 2026-06-29 | ↗ |
| MANCHESTER KEITH S | — | SELL | 600K | $34.59 | $20.75M | 2026-06-29 | ↗ |
| Gold Daniel Allen | — | SELL | 200K | $34.44 | $6.89M | 2026-06-29 | ↗ |
| Gold Daniel Allen | — | SELL | 600K | $34.59 | $20.75M | 2026-06-29 | ↗ |
| Epperly Melissa B, | — | SELL | 15K | $34.32 | $0.51M | 2026-06-29 | ↗ |
| QVT Financial LP | — | SELL | 200K | $34.44 | $6.89M | 2026-06-29 | ↗ |
| QVT Financial LP | — | SELL | 600K | $34.59 | $20.75M | 2026-06-29 | ↗ |
| Epperly Melissa B, | — | SELL | 3K | $34.71 | $0.10M | 2026-06-29 | ↗ |
| Sukhatme Mayukh | President & CIO | SELL | 500K | $34.08 | $17.04M | 2026-06-26 | ↗ |
| QVT Financial LP | — | SELL | 301K | $33.92 | $10.20M | 2026-06-26 | ↗ |
| QVT Financial LP | — | SELL | 325K | $34.07 | $11.07M | 2026-06-26 | ↗ |
| MANCHESTER KEITH S | — | SELL | 325K | $34.07 | $11.07M | 2026-06-26 | ↗ |
| MANCHESTER KEITH S | — | SELL | 301K | $33.92 | $10.20M | 2026-06-26 | ↗ |
| Gold Daniel Allen | — | SELL | 325K | $34.07 | $11.07M | 2026-06-26 | ↗ |
| Gold Daniel Allen | — | SELL | 301K | $33.92 | $10.20M | 2026-06-26 | ↗ |
| Sukhatme Mayukh | President & CIO | SELL | 500K | $34.13 | $17.07M | 2026-06-25 | ↗ |
| Venker Eric | President & Immunovant CEO | SELL | 46K | $33.51 | $1.55M | 2026-06-24 | ↗ |
| Venker Eric | President & Immunovant CEO | SELL | 154K | $33.05 | $5.08M | 2026-06-24 | ↗ |
| Venker Eric | President & Immunovant CEO | SELL | 200K | $30.27 | $6.05M | 2026-05-22 | ↗ |
| Venker Eric | President & Immunovant CEO | SELL | 200K | $29.59 | $5.92M | 2026-04-20 | ↗ |
| Gline Matthew | CEO | SELL | 290K | $29.16 | $8.45M | 2026-04-16 | ↗ |
| Humes Jennifer | Chief Accounting Officer | SELL | 14K | $28.37 | $0.38M | 2026-04-08 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| FMR LLC | SC 13G/A | 73.6M | 10.3% | 2026-03-06 | ↗ |
| SB Investment Advisers (UK) Limited | SC 13G/A | 16.4M | 2.3% | 2026-02-17 | ↗ |
| Ramaswamy Vivek | SC 13G/A | 48.4M | 6.8% | 2026-02-13 | ↗ |
| Morgan Stanley | SC 13G/A | 55.5M | 8.0% | 2026-02-11 | ↗ |
| FMR LLC | SC 13G/A | 65.8M | 9.5% | 2026-02-05 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.